Company: BDJ
Filing Date: 2025-03-07
Form Type: N-CSR
Source: 0001193125-25-049575
Chunk: 22

Company: BlackRock Enhanced Equity Dividend Trust
Filing Date: 2025-03-07
Form: N-CSR
Chunk 22
---
| MSCI ACWI                                               |                        17.49 |             10.22 |

| (a) | BMEZ commenced operations on January 30, 2020.                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:----|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (b) | All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.                                                                                                                                                                                                                                                                                                                                                                                                                          |
| (c) | TheTrust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.                                                                                                                                                                                                                                                                                                                                                           |
| (d) | An index representing the Health Care sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25% overwrite level. TheMSCI ACWI SMID Cap Growth Index captures mid- and small-cap securities exhibiting overall growth style characteristics across certain developed and emerging markets countries.The index commenced on March 31, 2022 and therefore the since inception return presented is for the period March 31, 2022 through the current reporting period. |

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results. The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance. More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com . The following discussion relates to the Trust’s relative performance based on NAV: What factors influenced performance? At the sector level, an underweight allocation to healthcare providers and services and security selection in pharmaceuticals contributed to relative performance. An out-of-benchmark position in Intuitive Surgical, Inc. was the leading contributor among the Trust’s individual holdings. The company experienced strong growth in the installations and procedural volumes for its da Vinci surgical robotic system, and it received U.S. Food and Drug Administration (“FDA”) approval for its latest-generation model in March 2024. An out-of-benchmark position in Argenx SE contributed, as well. The biotechnology company—which specializes in chronic autoimmune disorders—secured an FDA label expansion for its flagship drug, VYVGART, for its use in additional therapeutic indications. An out-of-benchmark position in Boston Scientific Corp